These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone. Zinman B Diabetes Obes Metab; 2001 Aug; 3 Suppl 1():S34-43. PubMed ID: 11685828 [No Abstract] [Full Text] [Related]
12. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Singh Ahuja H; Liu S; Crombie DL; Boehm M; Leibowitz MD; Heyman RA; Depre C; Nagy L; Tontonoz P; Davies PJ Mol Pharmacol; 2001 Apr; 59(4):765-73. PubMed ID: 11259621 [TBL] [Abstract][Full Text] [Related]
13. Euglycemic and hypolipidemic activity of PAT5A: a unique thiazolidinedione with weak peroxisome proliferator activated receptor gamma activity. Vikramadithyan RK; Chakrabarti R; Misra P; Premkumar M; Kumar SK; Rao CS; Ghosh A; Reddy KN; Uma C; Rajagopalan R Metabolism; 2000 Nov; 49(11):1417-23. PubMed ID: 11092504 [TBL] [Abstract][Full Text] [Related]
14. MK-0767, a novel dual PPARalpha/gamma agonist, displays robust antihyperglycemic and hypolipidemic activities. Doebber TW; Kelly LJ; Zhou G; Meurer R; Biswas C; Li Y; Wu MS; Ippolito MC; Chao YS; Wang PR; Wright SD; Moller DE; Berger JP Biochem Biophys Res Commun; 2004 May; 318(2):323-8. PubMed ID: 15120604 [TBL] [Abstract][Full Text] [Related]
16. Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation. Nugent C; Prins JB; Whitehead JP; Savage D; Wentworth JM; Chatterjee VK; O'Rahilly S Mol Endocrinol; 2001 Oct; 15(10):1729-38. PubMed ID: 11579205 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative. Shibata T; Matsui K; Nagao K; Shinkai H; Yonemori F; Wakitani K Eur J Pharmacol; 1999 Jan; 364(2-3):211-9. PubMed ID: 9932726 [TBL] [Abstract][Full Text] [Related]
18. PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation. Hong G; Davis B; Khatoon N; Baker SF; Brown J Biochem Biophys Res Commun; 2003 Apr; 303(3):782-7. PubMed ID: 12670479 [TBL] [Abstract][Full Text] [Related]
19. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention. Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887 [TBL] [Abstract][Full Text] [Related]
20. Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor gamma and hepatocyte nuclear factor 4alpha. Malerød L; Sporstøl M; Juvet LK; Mousavi A; Gjøen T; Berg T Biochem Biophys Res Commun; 2003 Jun; 305(3):557-65. PubMed ID: 12763030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]